Dr. Jackie Broadway-Duren shares an overview of expanding CLL treatment options, discussing newer BTK inhibitors, BCL-2 inhibitors, combination therapies, and emerging BTK degraders that are offering additional approaches for both newly diagnosed and relapsed patients.
Expert Panel:

Dr. Jackie Broadway-Duren, The University of Texas MD Anderson Cancer Center
Transcript:
Dr. Jackie Broadway-Duren: What I would like to share is that we are pretty much doing frontline therapy now with the BTK inhibitors, the covalent and non-covalent BTK inhibitors. Many of our patients are familiar with those. And those would include where we rarely are using ibrutinib (Imbruvica) anymore, but we have zanubrutinib, (Brukinsa) pirtobrutinib (Jaypirca), and acalubrutinib (Calquence). While Calquence, which many patients come to our clinics questioning that particular one because they see it on the commercials. We’re also using as frontline therapy in some cases for unmutated patients, the BTK-I as well as BCL-2, which will be your venetoclax (Venclexta) therapy.
Then there’s sequencing for CLL patients. Those who may have started out with BTK-Is and later developed a mutation for the BTK and needed to go on to non-covalent, which would be the pirtobrutinib, as well as combination therapies. So, as I was saying, for patients particularly with that initial relapse, they may or may not be rechallenged with a BTK-I. And they will likely have the – we’re doing a lot of combination therapies now where we’re combining BTK-Is as well BCL-2 and monoclonal antibody, which in most cases is obinutuzumab (Gazyva). However, there are a few cases, such as with the MERINO trial where methotrexate (Rheumatrex) was used instead.
And with these studies, we are seeing after three years progression for survivor, many of them are in the high 70s, around 80 percent in most of this patient population. They are now doing studies where they are combining the zanubrutinib as well with venetoclax. So, that’s still pretty early on. Most recently, we now have degraders, BTK degraders that we are using. So, those are exactly what they sound like where the BTK is attacking and degrading the protein that can drive the disease. So, this is very interesting. We do have some frontline protocols used in BTK degraders for untreated patients, as well as in patients who have been relapsed.
So, that’s just to give you a snapshot of where we are now. We also are combining now BTK degraders with a new BCL-2. Yes, we do have something other than venetoclax now. We have the sonrotoclax (Beqalzi), which is also being incorporated in some of the newer clinical trials. So, just to give you an idea, generally when patients come in and they are untreated, they may be started on single agent BTK inhibitors. As you know, many of the treatment decisions are based on what the prognostic factors look like, such like the FISH test and the next-generation sequencing and those type things.
And they also depend on the age of the patient and their physical status at the time. Whether they are well, whether they have multiple comorbidities that also can help drive and determine treatment strategies for that patient. And lastly, patients are considered for treatment and given the option for a time-limited or fixed-duration therapies. Some choose to just take maybe a BTK inhibitor for continuous. That is something that is decided with the physician and the team and the patient. They are part of the team. So, they get to have input also into those treatment decisions.